ModifiedUnitedHealthcarePolicy CS103ID.B

Prolotherapy and Platelet Rich Plasma Therapies (for Idaho Only)

Medical policy governing the use and coverage stance for prolotherapy and platelet-rich plasma therapies for members in the state of Idaho (including Idaho Medicaid Plus).

Policy Summary

PayerUnitedHealthcare

PolicyProlotherapy and Platelet Rich Plasma Therapies (for Idaho Only)

Policy CodePolicy CS103ID.B

Change TypeUpdated clinical evidence and references

Effective DateJune 1, 2026

Next Review DateN/A

Key ActionDo not authorize or consider coverage for prolotherapy or PRP for any indication in Idaho without documented justification, as these therapies are considered not medically necessary.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence and References sections to reflect the most current information.

CS103ID.Bpolicy identifier (Idaho-only)

2026-06-01effective date

2therapies declared not medically necessary

multiple RCTs & SRsevidence base discussed

minor AEssafety signals reported

Coverage Determinations and Evidence Summary

Not Medically Necessary

Covered stance

Not medically necessary for any indication: Prolotherapy and platelet-rich plasma therapies are considered unproven and not medically necessary for any condition or indication.

See policy coverage rationale.

Reported trial criteria and outcome patterns

Clinical trial inclusion patterns and reported effective scenarios (for provider reference):

Typical KOA trial inclusion criteria: Age ranges commonly mid-adult to older adults (examples: 48–80 years); symptomatic knee osteoarthritis with pain (e.g., VAS ≥4 in some trials) and radiographic Kellgren-Lawrence grade 2–3

Derived from multiple RCT descriptions; see cited trials.

Delivery approaches studied: Intra-articular, peri-articular, perineural, or combined injection approaches; dextrose concentrations varied widely (examples: 5% to 50%; HDP at 25% reported) and PRP protocols differed by leukocyte content, volume, and activation.

See trial methods and comparative designs.

Typical treatment regimens and follow-up: Regimens include single or serial injections (weekly to monthly; e.g., three weekly intra-articular PRP injections; 1–6 prolotherapy sessions) with follow-up assessments at 2–12 weeks and up to 12 months or longer in some studies.

See individual RCT designs and follow-up schedules.

Reported outcome patterns: Trials commonly report within-group improvements in pain and function; some studies show superiority versus saline, physiotherapy, or alternative injectables at select timepoints while others report no significant difference versus control—results are heterogenous across studies and endpoints.

See comparative trial outcomes and meta-analyses.

Condition-specific evidence summaries

Evidence-based summaries (condition-specific) — conclusions and limitations from cited studies and reviews

Lateral epicondylosis (tennis elbow): Dextrose prolotherapy and PRP have shown pain and function improvements in multiple RCTs and systematic reviews; pooled analyses favor DPT at 12 weeks for pain and DASH in some reviews, but study sizes and methods vary and risk of bias exists.

See Ciftci et al., Zhu et al., and larger RCTs and systematic reviews.

Rotator cuff tendinopathies: Evidence is mixed: some RCTs and reviews report short-term benefits of dextrose or PRP versus comparators, while others report worse physical performance versus corticosteroid for shoulder/bursal conditions; methodological limitations and heterogeneity reduce certainty.

See Ewart et al. and individual RCT reports.

Temporomandibular joint (TMJ) disorders: Systematic reviews and small RCTs suggest dextrose prolotherapy reduces TMJ pain and can improve mouth opening and related outcomes up to 12 months, but studies are few, heterogeneous, and small.

See Bahgat et al. and Saramantos et al.

Evidence summaries

Evidence-based findings and typical study conclusions

TMJ disorders - prolotherapy: Multiple systematic reviews and RCTs report pain reduction and some functional gains with dextrose prolotherapy versus placebo or other comparators, but small sample sizes and heterogeneity limit generalizability.

See Saramantos, Zhou, Bahgat.

Autologous blood injections for TMJ hypermobility: Autologous blood injections reduce dislocation episodes in many patients per systematic review data, but trial heterogeneity and variable protocols constrain strong conclusions.

See Chęciński et al.

Lower limb tendinopathies - prolotherapy: Small observational studies suggest intratendinous hyperosmolar dextrose with adjunct hydrodissection can reduce pain and neovascularization in Achilles tendinosis, but controlled RCT evidence is limited.

See Bello Baez and Morath.

KOA — evidence summary

Evidence-based considerations across indications

Knee Osteoarthritis (KOA): RCTs and systematic reviews show mixed results: some formulations (e.g., leukocyte-poor PRP) report sustained improvement at 12 months and meta-analyses favor PRP at 3–12 months, but heterogeneity of preparations and trial methods and at least one large RCT showing no difference versus saline leave conclusions uncertain.

Additional high-quality, standardized trials are needed.

Hip OA — evidence summary

Hip Osteoarthritis: Available RCTs and systematic reviews are small and low quality; no intra-articular hip injection (including PRP) demonstrated clinically meaningful benefit beyond saline placebo at up to 6 months in network analyses, and evidence overall is insufficient to support routine use.

See Gazendam et al. and Hayes HTA summaries.

Tendinopathies — evidence summary

Tendinopathies and soft-tissue injuries: Condition-specific data vary: PRP shows benefit for patellar and some lateral epicondylar tendinopathies in select RCTs and reviews, but evidence for Achilles and rotator cuff tendinopathy is limited or inconsistent; overall certainty is low to very low.

Heterogeneous preparations, small trials, and inconsistent outcomes limit confidence.

Surgical augmentation — evidence summary

Surgical augmentation with PRP: PRP used as an adjunct in ACL reconstruction, meniscal repair, or other surgical procedures may provide short-term pain or functional benefits in some analyses but does not demonstrate consistent long-term improvements in graft healing, failure rates, or sustained functional outcomes.

Meta-analyses and systematic reviews report limited or no proven long-term benefit.

Foot/Ankle — safety summary

Foot and ankle safety summary: Systematic review/meta-analysis data indicate higher overall complication rates with PRP for foot/ankle pathologies (reported complication rate 41.1% vs 33.7% for comparators) and an increased rate of post-injection pain; the estimated number needed to harm for any complication was 13.

Serious complications were rare but post-injection pain was significantly more frequent.

Indication-specific evidence summaries

Evidence summaries and implication statements by indication (as presented):

Plantar fasciitis: Meta-analyses and RCTs report PRP can improve VAS pain and some functional scores versus corticosteroid, ESWT, and placebo in multiple studies, but heterogeneity across trials and variable long-term outcomes reduce certainty.

See Herbert et al. and Hayes reviews.

Achilles tendinopathy: Evidence is limited and inconclusive for consistent functional benefit of PRP versus controls; safety analyses show higher rates of postinjection pain but few serious adverse events.

See Fucaloro et al. and Hayes assessments.

Rotator cuff / shoulder: Some meta-analyses report short-term pain/function improvements and possible reduced retear rates with PRP augmentation, but long-term benefits are inconsistent and evidence quality is low to very low.

See Balasubramaniam, Moraes, and guideline summaries.

Coverage-relevant evidence summaries

Coverage considerations based on available evidence (use exact logical structure from studies when possible):

Foot injuries (talar OCL adjunct): Small RCT evidence suggests PRP plus HA or PRP alone may improve midterm AOFAS and VAS scores after microfracture for talar OCLs, but small sample sizes and short follow-up limit strength of recommendation; consider PRP adjunct only in selected postoperative cases after standard care fails.

See Görmeli et al.; evidence rated low quality.

Low back pain — general: Multiple small RCTs and systematic reviews report mixed results for PRP versus controls across discogenic, facet, and SIJ indications; heterogeneity in preparation and small samples limit certainty—PRP may be considered investigational outside documented research contexts.

See Zhang, Singh, Won, Zielinksi, Tuakli-Wosornu studies.

Intradiscal PRP for discogenic LBP: Prospective uncontrolled studies and small RCTs report pain and function improvements up to 48 weeks in some cohorts but randomized evidence is limited and adverse events (e.g., one discitis) have been reported; intradiscal PRP remains investigational pending larger RCTs and standardized protocols.

Guideline and evidence summaries by indication

Guideline and systematic review conclusions summarized by indication

Chronic wounds (general): Systematic reviews and meta-analyses (e.g., Martinez-Zapata) conclude evidence is inconclusive that autologous PRP improves healing of chronic wounds overall; evidence quality is low and findings are uncertain.

Cochrane/meta-analysis conclusions.

Diabetic foot ulcers: Some systematic reviews and HTAs report PRP may increase healing of diabetic foot ulcers (moderate SOE), but NICE recommends PRP gel not be offered for diabetic foot problems outside clinical trials; routine adoption is not supported without further evidence.

See Qu et al., ECRI, Hayes, and NICE guidance.

Knee osteoarthritis (guideline summary): AAOS indicates PRP may reduce pain and improve function based on low-quality evidence, whereas other bodies (ACR, AAHKS, VA/DoD) either recommend against routine use or state insufficient evidence to recommend PRP for hip/knee OA; NICE advises use only with special arrangements for governance and research.

See AAOS, ACR, AAHKS, NICE, VA/DoD statements.

UnitedHealthcare (Idaho) considers prolotherapy and platelet-rich plasma (PRP) therapies to be unproven and not medically necessary for any condition or indication owing to insufficient evidence of efficacy.

Some randomized trials of dextrose prolotherapy for knee osteoarthritis excluded participants outside the moderate radiographic severity range; for example, Bennell and other trial designs and related studies commonly enrolled patients with Kellgren‑Lawrence grade 2 or 3, while studies sometimes excluded patients with KL grade 1 or 4 from analyses.

Authors and systematic reviewers repeatedly note insufficient evidence to confirm long-term clinical usefulness for prolotherapy and PRP, and highlight the need for higher-quality, longer follow-up studies before routine adoption can be supported.

A major limitation across the evidence base is the heterogeneity and lack of standardization in preparation and administration (for PRP: leukocyte content, volume, activation; for prolotherapy: concentration and injection technique), which reduces comparability across studies and undermines firm conclusions.

Evidence is insufficient for many soft‑tissue indications — systematic reviews and Cochrane assessments conclude that, for conditions such as rotator cuff tendinopathy and other tendon disorders, the current trials are small, heterogeneous, and of low or very low certainty, preventing routine recommendation.

Across multiple reviews, study results are characterized by substantial clinical and methodological heterogeneity and generally low or very low certainty of evidence, limiting confidence in reported treatment effects.

For chronic venous leg ulcers (VLUs), systematic reviews and technology assessments report mixed findings and conclude that the evidence is insufficient and inconclusive to support routine use of PRP; routine coverage for chronic VLUs is therefore not supported by conclusive evidence.

NICE recommends that autologous PRP gel should not be offered for diabetic foot problems unless used within a clinical trial, and that where PRP is used for knee OA it should be within special arrangements for governance, consent, audit, or research.

Given the overall uncertainty and inconsistent findings across indications, prolotherapy and PRP remain not medically necessary in Idaho due to insufficient evidence demonstrating consistent clinical benefit.

Systematic reviews of dextrose prolotherapy (DPT) report limited or little-to-no benefit compared with normal saline for knee osteoarthritis in some analyses, and methodological limitations (small trials, risk of bias, and heterogeneity) weaken the evidence base.

Study limitations commonly highlighted include inconsistent PRP/prolotherapy protocols, small sample sizes, short follow-up, varying outcome measures, and high risk of bias — factors that render many results inconclusive and prevent broad clinical recommendations.

Bennell et al. (2021), a large double‑blind RCT (n = 288) of leukocyte‑poor PRP versus saline in mild‑to‑moderate medial knee OA, found no difference in symptoms or MRI‑assessed joint structure at 12 months, leading the authors to conclude that PRP did not support use for that population in that trial.

For hip osteoarthritis, network meta‑analysis and RCT evidence are small and of low quality; current randomized evidence does not show a clinically meaningful benefit of PRP over placebo up to 6 months, and larger, better‑designed trials are required.

Authors conclude that evidence is insufficient to routinely recommend ultrasound‑guided PRP injections for tendinopathies because certainty is low or very low, study methods vary widely, and comparative effectiveness versus standard treatments is unclear.

Meta‑analyses and technology assessments for chronic wounds report inconclusive results overall; while PRP may increase healing for some diabetic foot ulcers, the evidence quality is low, and autologous PRP cannot be concluded to be effective for all chronic wounds based on current trials.

Professional guidelines vary but trend toward caution: the ACR strongly recommends against PRP for knee and hip osteoarthritis and AAHKS states that biologic therapies including PRP cannot currently be recommended for advanced hip or knee arthritis, reflecting guideline‑level skepticism about routine PRP use.

Applicable Procedure and Billing Codes

Applicable procedure/HCPCS/CPT codesmixed

0232T	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed.
G0460	Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers (includes, as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment)
G0465	Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication (includes as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment)
M0076	Prolotherapy
P9020	Platelet rich plasma, each unit

No explicit billing codes providedmixed

No codes listed

No explicit CPT/HCPCS/ICD codes listed in this excerptmixed

No codes listed

Kellgren‑Lawrence grade inclusion — KOA trials

Kellgren-Lawrence grade inclusionGrade 2 or 3 (mild to moderate osteoarthritis used as trial eligibility)

Authorization, Documentation, and Operational Guidance

Denial Risk

Prior authorization / coverage stance (Idaho)

For Idaho plans: Prolotherapy and platelet-rich plasma (PRP) are considered unproven and not medically necessary; claims billed with the procedure codes listed in this policy may be denied.

Applicable codes: 0232T; G0460; G0465; M0076; P9020

Prior Authorization

Prior authorization — not specified

This excerpt does not specify any statewide or plan-level prior authorization program or explicit prior authorization form or process for PRP or prolotherapy.

Clinical and Procedural Background

Prolotherapy is an injection‑based treatment intended to stimulate a healing response by injecting agents such as dextrose, saline, or local anesthetic into ligaments, tendons, or joint structures to promote tissue repair and reduce pain; descriptions emphasize variable concentrations and techniques across studies.

Key Definitions

Prolotherapy definition — injection substances listed

Prolotherapy — injectable agentsCommonly injected substances include dextrose, normal saline, sarapin, procaine, and lidocaine.

Platelet‑rich plasma (PRP) definition

PRP — basic definitionAn autologous blood preparation with concentrated platelets, platelet-derived growth factors, and cytokines intended to stimulate tissue regeneration and repair.

Dextrose prolotherapy (DPT / HDP) definition

Dextrose prolotherapy (DPT/HDP) — therapy descriptionInjection therapy using hypertonic/hyperosmolar dextrose solutions delivered intra‑articularly or peri‑articularly; concentrations reported in trials range (examples include 5% up to 50%, with HDP noted at 25% in one study).

Policy Revision History

2026-06-01archived_previous_versionLatest

Archived previous policy version CS103ID.A when issuing CS103ID.B and updated clinical evidence and references.

Policy Summary

PayerUnitedHealthcare

PolicyProlotherapy and Platelet Rich Plasma Therapies (for Idaho Only)

Policy CodePolicy CS103ID.B

Change TypeUpdated clinical evidence and references

Effective DateJune 1, 2026

Next Review DateN/A

Key ActionDo not authorize or consider coverage for prolotherapy or PRP for any indication in Idaho without documented justification, as these therapies are considered not medically necessary.

SourceLink

On This Page

Lower limb tendinopathies (Achilles, patellar): Observational series and some RCTs report pain reduction and functional gains with prolotherapy or PRP for certain tendinopathies; evidence is stronger for patellar and lateral epicondylar tendinopathy than for Achilles or rotator cuff, but overall quality remains low to moderate.

See Bello Baez, Morath, Balasubramaniam, and Barman reviews.

Knee osteoarthritis: Systematic reviews and meta-analyses report PRP may improve pain and function versus HA, steroids, or placebo at some timepoints (notably 6–12 months), but results are heterogeneous; a large RCT (Bennell et al.) found no difference versus saline at 12 months, raising uncertainty about routine benefit.

See Filardo et al., ECRI, Bennell et al.

PRP for knee osteoarthritis - summary: Meta-analyses indicate PRP can yield better pain and functional scores versus HA, corticosteroids, and placebo at 3–12 months in pooled data, yet evidence is low quality and heterogenous; large trials (e.g., Bennell et al.) challenge consistent benefit at 12 months.

See Filardo et al., Bennell et al., ECRI.

Lateral epicondylitis: Evidence is mixed: some trials and meta-analyses show longer-term benefit of PRP over corticosteroids after 3–6 months, while other analyses find comparable outcomes across interventions; transient injection-site pain is common.

See Masiello et al., ECRI analyses.

Osteochondral lesions / talar OCL adjunct: A small RCT reported improved AOFAS and VAS scores with PRP versus control after arthroscopic microfracture for talar OCLs, but study size and follow-up limit generalizability.

See Görmeli et al.

Low back pain: Small RCTs and meta-analyses across etiologies (discogenic, facet, SIJ) show mixed results; some studies report short-term equivalence to steroids or lidocaine and occasional superiority at select timepoints, but overall evidence is insufficient to define routine use.

See Zhang 2024 network meta-analysis and multiple small RCTs.

See Zhang 2022 and Tuakli-Wosornu 2016.

Facet joint and SIJ injections: Some small RCTs reported longer duration of efficacy with PRP versus steroid/local anesthetic, but sample sizes and follow-up are limited; consider only for select patients after standard therapies fail and ideally within research frameworks.

See Wu 2017, Singla 2017, and related trials.

Wounds — diabetic foot ulcers (DFUs): Systematic reviews and HTAs indicate PRP added to conventional wound therapy may increase complete wound closure and shorten time to closure for hard-to-heal DFUs (moderate to low strength of evidence), but heterogeneity in protocols and reporting limit definitive recommendations; PRP may be considered as an adjunct for refractory DFUs with documented prior conventional therapy failure.

See Hayes, ECRI, Qu et al., and Martinez-Zapata analyses.

Wounds — VLUs and pressure ulcers: Evidence for venous leg ulcers and pressure ulcers is inconclusive or insufficient to support routine PRP use; routine coverage is not supported outside clinical trials or specialized programs.

See Hayes VLU HTA and Martinez-Zapata review.

Rotator cuff and shoulder: AAOS recommendations do not support routine PRP use for rotator cuff tendinopathy or augmentation based on limited or strong evidence against benefit for many contexts, though limited data suggest possible reduced retear rates with liquid PRP.

See AAOS guideline statements.

Low back pain / spine injections: ASIPP classifies intradiscal PRP evidence as Level III and facet/SIJ injections as Level IV, recommending careful, responsible use with appropriate precautions and adherence to regulatory guidance; evidence remains limited.

See ASIPP guideline summary.

Note

Prior authorization — check plan terms

Check the member's specific federal/state/contractual plan terms and benefit documents before applying this policy; when plan terms conflict with this Medical Policy, the federal/state/contract governs.

Note

Evidence variability risk

PRP and prolotherapy evidence is heterogeneous: PRP preparations, application methods, and study protocols vary widely across conditions and trials, producing inconsistent efficacy estimates and limiting generalizability and patient selection guidance.

Heterogeneity in PRP prep, leukocyte content, volume, number/timing of injections
Variable comparators (HA, corticosteroid, saline, exercise) and follow-up intervals
Inconsistent reporting of PRP composition and outcomes

Denial Risk

Safety signal — post-injection pain

Safety signals have been reported: PRP recipients have higher rates of post-injection treatment-site pain versus comparators in some foot/ankle studies (number needed to harm ~13) and injection-site pain/ecchymosis is a commonly reported adverse event across trials.

Higher odds of post-injection pain for PRP (OR = 2.23) in foot/ankle meta-analysis; NNH = 13
Common transient AEs: injection-site pain, ecchymosis; rare serious events reported (e.g., one case of severe pain requiring surgery)

Note

Unclear protocol / patient selection

Protocols and patient selection remain unclear: studies use differing inclusion criteria, PRP formulations, injection techniques, and outcome measures, so specific clinical subgroups most likely to benefit are not well defined.

Lack of standardized indications or validated selection criteria across conditions
Variable blinding and follow-up durations limit inference about which patients benefit

Documentation Required

Special arrangements recommended by NICE

NICE recommends special arrangements when offering PRP: use only with appropriate clinical governance, explicit consent, audit or research arrangements, and only in the context of studies where evidence is limited.

For KOA: use only with special arrangements for governance, consent, and audit or research
For diabetic foot: PRP gel should not be offered outside clinical trials

Documentation Required

Suggested documentation from trial methods

When prior authorizing or documenting PRP/prolotherapy in trials, document concurrent conservative therapies and trial methods commonly used in higher-quality studies (e.g., ultrasound guidance, concurrent exercise or physical therapy, standardized outcome instruments and timing).

Document prior conservative care tried (physical therapy, medications, activity modification) and dates/duration
Record use of ultrasound guidance and concurrent therapeutic exercise or rehab protocols
Use standardized outcome measures (WOMAC, KOOS, VAS, performance tests) and baseline plus scheduled follow-up assessments

Documentation Required

Governance, consent, and off-label use documentation

Follow governance and consent best practices for off-label use: obtain informed consent that explains limited/variable evidence and potential risks; consider audit, registry enrollment, or research oversight when offering PRP or prolotherapy off label.

Document informed consent detailing off-label status and uncertain long-term benefit/safety
Record PRP composition when available (platelet/WBC counts) and method of preparation
If used, consider enrollment in registry or research and local clinical governance review

Step Therapy

No explicit step therapy requirements

No formal step therapy algorithms are specified in this excerpt; the evidence summaries do not define mandatory stepwise requirements in the policy text provided.

Step Therapy

Step therapy preference — conservative care and alternative injectables

Clinical practice preference reflected in the evidence base: before PRP or prolotherapy, many studies enrolled participants refractory to first-line conservative care; consider requiring documented trials of conservative therapy (e.g., physical therapy, analgesics) and/or alternative injectable options (corticosteroid or hyaluronic acid) prior to approving PRP/prolotherapy.

Require documentation of failed conservative care (duration and modalities)
Consider trial of alternative injectable agents (corticosteroid, HA) unless contraindicated or not clinically appropriate

DPT / HDPT — entheses and peritendinous injections definition

Entheses and peritendinous DPT injections — definitionInjection of hypertonic dextrose into entheses, tendons, bursae, or peritendinous tissues (often ultrasound‑guided) targeting tendon/enthesis pain and dysfunction.

Dextrose prolotherapy general definition

Dextrose prolotherapy — general intentDirected injections intended to provoke a mild inflammatory response to stimulate growth of new ligament or tendon fibers and strengthen weakened connective tissue.

PRP — autologous blood‑derived plasma fraction definition

PRP — autologous blood‑derived plasma fractionAutologous plasma fraction with concentrated platelets used as an intra‑articular or soft‑tissue injectable therapy; preparations vary and are not standardized.

Leukocyte‑rich (LR) PRP — definition and adverse event association

Leukocyte‑rich (LR) PRP — definition and safety noteA PRP preparation with higher leukocyte content; some reports associate LR‑PRP with increased local adverse events compared with leukocyte‑poor PRP.

LP‑PRP — leukocyte‑poor PRP mention

LP‑PRP (leukocyte‑poor PRP)Leukocyte‑poor PRP preparations (used in some RCTs) — noted in trials reporting sustained functional improvement at 12 months in KOA.

PRP heterogeneity — variability in preparations and techniques

PRP heterogeneityPRP preparations and techniques vary across studies (leukocyte‑rich vs leukocyte‑poor, platelet/WBC concentrations, activation methods, volumes, and number/timing of injections), limiting comparability of results.

Intradiscal PRP — definition and study variability

Intradiscal PRP — definitionInjection of autologous PRP directly into the intervertebral disc to treat discogenic low back pain; reported studies vary in platelet counts and often lack detailed compositional reporting.

Prolotherapy / PRP procedures — procedural treatment definition

Prolotherapy / PRP procedures — procedural definitionProcedural treatments involving targeted injections (e.g., hypertonic dextrose for prolotherapy; autologous platelet concentrates for PRP) performed with image guidance as needed; agents/devices used may be subject to FDA regulation though the procedures themselves are not FDA‑regulated products.